Delacth has experienced strong growth for its HEPZATO treatment and trades at an attractive valuation. However, it faces both current and future competitive pressures that will likely weigh down sentiment and valuation multiples.Like millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and ...